In 2017, the market size of Chinese medicine tablets will reach 233 billion

Chinese medicine tablets are the traditional Chinese medicine industry in China and have been included in the scope of national key protection. In recent years, China's Chinese medicine tablet industry has developed rapidly, with the market size increasing from 85.37 billion yuan in 2011 to 195.6 billion yuan in 2016, with a compound annual growth rate of 19%, leading the pharmaceutical industry in all sectors. Industry insiders told China Securities News that the market size of Chinese medicine tablets is expected to reach 233 billion yuan in 2017 and 273.4 billion yuan in 2018.2006-2015, the total output value of the pharmaceutical industry increased from 473.73 billion yuan to 255.371 billion yuan, with a compound annual growth rate of 18.35 percent, according to
Financial Big Data Terminal Data Terminal Data. Among them, chemical raw materials, chemical preparations, Chinese medicine, biopharmaceuticals four sub-industries, 2006-2015 compound annual growth rate of 13.4%, 17.02%, 17.2%, 17.2%, respectively. 75% and 22.6%, and sales revenue in the Chinese medicine and beverage tablet industry increased from 19.02 billion yuan to 161.15 billion yuan, with a compound annual growth rate of 23.82 percent, the highest growth rate in the sub-industry. The share of sales revenue from Chinese medicine tablets in the total output value of the pharmaceutical industry increased from 4.02% in 2006 to 6.5% in 2015.
chinese medicine drinking tablets is China's traditional Chinese medicine industry, has been included in the scope of national key protection. In several revised versions of the Foreign Investment Industry Guidance Directory, foreign investment in "the application of traditional Chinese medicine tablet manufacturing technology and the production of Chinese traditional medicine secret recipe products" is explicitly prohibited, and the export of "Chinese medicine beverage tablet preparation technology" is prohibited.
in the removal of "drug-based medicine" environment, Chinese medicine tablets enjoy special treatment, still enjoy the benefits of drug added. The State Health and Planning Commission has requested that all domestic public hospitals abolish drug charges by the end of September 2017, with the exception of Chinese medicine tablets. With this generous treatment, hospitals will increase the use of Chinese medicine tablets in order to reduce losses. In addition, the state three orders five Shen to reduce the "drug proportion", in 2017 the pilot city public hospital drug proportion must be reduced to about 30% overall, but Chinese medicine tablets were again excluded. The policy of reducing the proportion of medicines is expected to result in a reduction of 100 billion yuan in the cost of medicines, and the enjoyment of Chinese medicine tablets as substitutes for chemical and Chinese medicine is in good interest.
industry said that under the policy of good driving, the market size of Chinese pharmaceutical tablets is expected to reach 233 billion yuan in 2017 and 273.4 billion yuan in 2018.industry is facing a reshuffle
the industry concentration is a major feature of the Chinese medicine tablet industry, sales of less than 100 million enterprises accounted for 70%, the industry leader Kangmei Pharmaceutical market share of only 2.4%.
Many small Chinese medicine beverage tablet enterprises on the market from the traditional hand workshop transformation, the use of backward production and management methods, the production of drugs in the quality of pharmaceutical raw materials, preparation technology, packaging, storage and transportation, there are various problems, directly affecting the clinical efficacy and safety of Chinese medicine tablets.
new version of GMP certification, introduced in 2011, strict requirements are given to all aspects of the production activities of Chinese medicine and beverage tablets enterprises (production, quality, control, storage, distribution and transportation). It is stipulated that enterprises that have not passed the GMP certification by the end of 2015 may not continue to produce drugs, and companies that have passed the GMP certification will face flight inspections at any time and will withdraw the GMP certificates issued if they are found to be in question.
statistics show that as of October 2015, the number of Chinese medicine tablets enterprises in China 1006, of which 500 by the end of 2015 did not pass the new version of GMP certification;
under regulatory pressure, small businesses are so far from demanding that they cannot afford the huge costs of retrofitting production lines and can only exit the market. Industry insiders, a Chinese pharmaceutical enterprises generally have two or three production lines, to produce hundreds of varieties, lot numbers, less production. If you want to transform the original production line into a regular assembly line, you need to invest at least 12 million yuan. This is a huge expense for small businesses. Chinese medicine tablet companies that fail to meet GMP requirements face the risk of closure or merger, and the industry faces a reshuffle. (China Securities News)